Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AstraZeneca, Bristol-Myers Say FORXIGA Gets Positive CHMP Opinion In EU

RELATED NEWS
Trade AZN now with 

AstraZeneca Plc (AZN: Quote,AZN.L) and Bristol-Myers Squibb Co. (BMY: Quote) said that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has recommended the approval of FORXIGA (dapagliflozin) tablets for the treatment of type 2 diabetes, as an adjunct to diet and exercise, in combination with other glucose-lowering medicinal products including insulin, and as a monotherapy in metformin intolerant patients.

The positive opinion was reached after the CHMP reviewed data from a comprehensive clinical development programme that included 11 core Phase III trials assessing the safety and efficacy of dapagliflozin as a once-daily oral therapy.

Dapagliflozin is an investigational selective and reversible inhibitor of sodium-glucose co-transporter 2, which works independently of insulin.

The companies noted that the CHMP's positive opinion on dapagliflozin will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.

Click here to receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Here is a quick summary of the earnings reported after the bell on Nov 19. Keurig Green Mountain, Inc. (GMCR) reported net income for the fourth quarter of $141.1 million or $0.86 per share, compared to $127.0 million or $0.83 per share for the year-ago quarter. Excluding items, adjusted net... Women's apparel retailer L Brands, Inc. said Wednesday that its third quarter profit rose 43% from last year, as sales increased 7%. The company's quarterly earnings per share also came in above analysts' expectations. At the same time, the company forecasts fourth quarter earnings below analysts' current consensus estimate, but once again raised its full year earnings outlook.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.